Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
Aurinia Pharmaceuticals→Kezar Life Sciences
Mar 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Tracking 274 merger M&A deals. Browse merger transactions across all sectors and states.
Aurinia Pharmaceuticals→Kezar Life Sciences
Mar 30, 2026
Aurinia Pharma→Kezar Life Sciences
Mar 30, 2026
Kinderhook Industries→Enhabit
Mar 30, 2026
Boston Scientific→Penumbra
Mar 30, 2026
Universal Health Services→Talkspace
Mar 28, 2026
Equitable→Corebridge
Mar 27, 2026
CrossCountry Intermediate Holdco→Two Harbors Investment
Mar 27, 2026
Infosys→Stratus
Mar 26, 2026
Corebridge Financial→Equitable
Mar 26, 2026
Corebridge Financial→Equitable Holdings
Mar 26, 2026
TWO→CrossCountry Mortgage
Mar 26, 2026
Corebridge Financial
Mar 26, 2026
Apex Companies→AquaWorks DBO
Mar 25, 2026
Innovation Beverage Group→BlockFuel Energy
Mar 25, 2026
GIC Real Estate→Veris Residential
Mar 25, 2026
Merck Sharp & Dohme→Terns Pharmaceuticals
Mar 25, 2026
Wawanesa Mutual Insurance Company→Everest Insurance Company of Canada
Mar 24, 2026
Trian→Janus Henderson Group
Mar 24, 2026
Xtend AI Robotics→JFB Construction Holdings
Mar 24, 2026
Fundrise eREIT
Mar 24, 2026